CDK4 and ovarian cancer: With the realization of the non-mitotic mechanism of paclitaxel in killing cancer cells (68), a new rationale may motivate the study of adding CDK4/6i to paclitaxel regimen, especially to the dose dense treatment of metastatic breast and recurrent ovarian cancer (Figure 3).